NDAORALCAPSULE, EXTENDED RELEASE
Approved
May 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VERELAN (verapamil hydrochloride) by R-Pharm US is mechanism of action essential hypertension verapamil hcl exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/minute is uncommon). First approved in 1990.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERELAN is an oral extended-release capsule formulation of verapamil hydrochloride, a calcium channel blocker approved in 1990 for essential hypertension. It works by dilating peripheral arterioles and reducing systemic vascular resistance, thereby lowering blood pressure without causing orthostatic hypotension or reflex tachycardia. The drug is particularly valued for its ability to reduce arterial pressure at rest and during exercise.
LOE Approaching
As a mature, near-LOE product with moderate competitive pressure (30%), VERELAN brand teams are focused on defensive positioning and cost management rather than expansion.
Mechanism of Action
Mechanism of Action Essential Hypertension Verapamil HCl exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/minute is uncommon). Verapamil HCl regularly…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VERELAN offers stability in a mature product with established market presence, but limited growth upside and shrinking headcount as LOE approaches. Career progression is best suited for professionals comfortable with defensive strategies, cost optimization, and transition planning in a declining franchise.
Brand Manager
Worked on VERELAN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.